Asia
Three companies on different continents raised more than $250 million to advance their scientific visions of supporting and developing new therapies for life-threatening diseases.
Temasek has committed $200 million to launch The G2 Bio Companies which focuses on the development of potential next-generation gene therapies.
Landos Biopharma partnered with Shanghai, China-based LianBio to develop and commercialize omilancor and NX-13 in Greater China and select Asian markets.
Proxalutamide, a selective high-affinity silent antagonist of the androgen receptor, is being developed by Chinese biotech, Kintor Pharmaceutical Limited (9939.HK).
The help wanted signs are up across the biopharma industry. Companies are opening and expanding facilities, which is good news for job seekers.
Although a quiet week for COVID-19-related clinical trial announcements, there were plenty of others. Read on for more information.
SpliSense, which focuses on cystic fibrosis and other genetic pulmonary diseases, closed on a $28.5 million Series B financing round. The company plans to use the money to advance its pipeline.
Biopharma and life sciences from across the globe provide updates on their businesses and pipelines.
Shanghai-based Alebund Pharmaceuticals has raised $60 million in a new Series B financing round that will be harnessed to further drive the company’s focus on renal disease.
There’s a fair amount of new information coming out about COVID-19 and vaccines. Here’s a roundup of some of the top stories.
PRESS RELEASES